|Gebot||71,16 x 50000|
|Briefkurs||71,18 x 50000|
|Tagesspanne||71,40 - 72,06|
|52-Wochen-Spanne||54,85 - 84,73|
|Beta (5 J., monatlich)||0,40|
|Kurs-Gewinn-Verhältnis (roll. Hochrechn.)||17,37|
|EPS (roll. Hochrechn.)||N/A|
|Erwartete Dividende & Rendite||2,72 (3,78%)|
|Ex-Dividendendatum||14. Juni 2023|
NORHAMPTON, MA / ACCESSWIRE / November 10, 2022 / Gilead Sciences While Jesse Garcia was growing up in Chicago's inner city, his parents didn't immediately turn to a doctor when someone in the family got sick. "We relied on traditional Latino ...
NORTHAMPTON, MA / ACCESSWIRE / November 2, 2022 / Gilead Sciences Since the beginning of the COVID-19 pandemic, Gilead's first-in-class antiviral was made available to more than 11 million patients globally- over 65% of whom live in low-and lower-middle-income ...
In the spring of 2018, North Carolina native Stephanie Walker went to her first breast cancer conference and had a revelation that she refers to as her "coming-out party." She learned she had metastatic breast cancer three years earlier and although she was a retired hospice nurse, she faced the disease without any guidance from others who shared her experience.
Gilead Sciences, Inc. (Nasdaq:GILD) recently announced that the Gilead Foundation's Creating Possible Fund™ will provide a total of $20 million to 13 inaugural grantees. The Creating Possible Fund was launched to support creative and high-impact strategies that advance health through education equity, with a main focus on building a pipeline of Black health leaders.